Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial.

Ebrahimpour-Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi M.

Phytomedicine. 2018 May 15;44:39-44. doi: 10.1016/j.phymed.2018.03.050. Epub 2018 Mar 19.

PMID:
29895491
2.

Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

Li WY, Yu G, Hogan RM, Mohandas R, Frye RF, Gumpricht E, Markowitz JS.

Clin Ther. 2018 Jan;40(1):103-113.e1. doi: 10.1016/j.clinthera.2017.11.013. Epub 2017 Dec 19.

PMID:
29273470
3.

Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.

Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Mahdavi M, Alipour A, Aliasgharian A.

Phytother Res. 2018 Mar;32(3):496-503. doi: 10.1002/ptr.5995. Epub 2017 Dec 13.

PMID:
29235162
4.

The impact of silymarin on antioxidant and oxidative status in patients with β-thalassemia major: A crossover, randomized controlled trial.

Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Alipour A, Shaki F, Aliasgharian A.

Complement Ther Med. 2017 Dec;35:25-32. doi: 10.1016/j.ctim.2017.08.007. Epub 2017 Aug 24.

PMID:
29154063
5.

The Long-Term Efficacy of a Galactagogue Containing Sylimarin-Phosphatidylserine and Galega on Milk Production of Mothers of Preterm Infants.

Serrao F, Corsello M, Romagnoli C, D'Andrea V, Zecca E.

Breastfeed Med. 2018 Jan/Feb;13(1):67-69. doi: 10.1089/bfm.2017.0169. Epub 2017 Nov 17.

PMID:
29148822
6.

High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial.

Fathalah WF, Abdel Aziz MA, Abou El Soud NH, El Raziky MES.

J Interferon Cytokine Res. 2017 Nov;37(11):480-487. doi: 10.1089/jir.2017.0051.

PMID:
29135373
7.

Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.

Voroneanu L, Siriopol D, Dumea R, Badarau S, Kanbay M, Afsar B, Gavrilovici C, Covic A.

Int Urol Nephrol. 2017 Dec;49(12):2195-2204. doi: 10.1007/s11255-017-1697-5. Epub 2017 Sep 25.

PMID:
28948420
8.

Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes.

Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, Gentile S.

J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):495-502.

PMID:
28685558
9.

Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Elyasi S, Shojaee FSR, Allahyari A, Karimi G.

Phytother Res. 2017 Sep;31(9):1323-1329. doi: 10.1002/ptr.5857. Epub 2017 Jun 21.

PMID:
28635153
10.

Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial.

Asgarshirazi M, Shariat M, Sheikh M.

Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):296-302.

PMID:
28603098
11.

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.

Wah Kheong C, Nik Mustapha NR, Mahadeva S.

Clin Gastroenterol Hepatol. 2017 Dec;15(12):1940-1949.e8. doi: 10.1016/j.cgh.2017.04.016. Epub 2017 Apr 15.

PMID:
28419855
12.

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Xie Y, Miranda SR, Hoskins JM, Hawke RL.

Molecules. 2017 Jan 15;22(1). pii: E142. doi: 10.3390/molecules22010142.

13.

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):289-296. doi: 10.1097/MEG.0000000000000789.

PMID:
27906753
14.

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M.

BMC Psychiatry. 2016 Nov 15;16(1):398.

15.

Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.

Elyasi S, Hosseini S, Niazi Moghadam MR, Aledavood SA, Karimi G.

Phytother Res. 2016 Nov;30(11):1879-1885. doi: 10.1002/ptr.5704. Epub 2016 Aug 23.

PMID:
27555604
16.

Efficacy of a galactogogue containing silymarin-phosphatidylserine and galega in mothers of preterm infants: a randomized controlled trial.

Zecca E, Zuppa AA, D'Antuono A, Tiberi E, Giordano L, Pianini T, Romagnoli C.

Eur J Clin Nutr. 2016 Oct;70(10):1151-1154. doi: 10.1038/ejcn.2016.86. Epub 2016 Jun 1.

PMID:
27245206
17.

Evaluation of the galactogogue effect of silymarin on mothers of preterm newborns (<32 weeks).

Peila C, Coscia A, Tonetto P, Spada E, Milani S, Moro G, Fontana C, Vagliano L, Tortone C, Di Bella E, Bertino E.

Pediatr Med Chir. 2015 Dec 29;37(3):pmc.2015.105. doi: 10.4081/pmc.2015.105.

18.

A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A.

BMC Complement Altern Med. 2015 Sep 23;15:334. doi: 10.1186/s12906-015-0861-7.

19.

The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus.

Derosa G, D'Angelo A, Maffioli P.

Clin Nutr. 2016 Oct;35(5):1091-5. doi: 10.1016/j.clnu.2015.08.004. Epub 2015 Sep 2.

PMID:
26384091
20.

Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.

Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, Mora N, González JM, de Luis DA.

Eur Rev Med Pharmacol Sci. 2015 Aug;19(16):3118-24.

Supplemental Content

Loading ...
Support Center